Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > MBX Q4 Earnings

<< Previous

Bullboard Posts

Next >>

Comment by rjc7on Dec 21, 2023 8:48am

168 Views

Post# 35795386

RE:RE:MBX Q4 Earnings

Agree. Also, and you touched on this somewhat, none of the good news that we've been receiving lately is reflected in this report. The bulk of the good stuff was reported after September 30. Q1 is almost done and should show some positive results with some of the agreements they have just made. I think the worst is over........ "More happily, Microbix expects record sales across fiscal 2024, along with significantly positive net earnings"

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles